*Disclaimer

EMYRIA LIMITED (ASX: EMD)

🔗 📄 📈

EMD: Pax Centre Acquisition to Advance Psychedelic Therapies

EMYRIA LIMITED

2023-07-03 09:47:00

EMD: Emyria Receives Ethics Approval for MDMA-assisted Therapy

EMYRIA LIMITED

2023-06-08 09:10:00

EMD: Emyria Completes $2.5m Placement

EMYRIA LIMITED

2023-05-01 10:07:00

EMD: Emyria Unveils Highest Potency CBD Capsule for FDA Pathway

EMYRIA LIMITED

2023-04-24 09:25:00

EMD: Emyria to Develop Psilocybin Therapy Care Model

EMYRIA LIMITED

2023-04-18 08:15:00

EMD: Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5

EMYRIA LIMITED

2023-04-04 08:53:00

EMD: Strong Recruitment for EMD-RX5 Phase 3 Trial

EMYRIA LIMITED

2023-03-23 08:16:00

EMD: Emyria Grows MDMA Asset for Neuro & Mental Health Therapy

EMYRIA LIMITED

2023-03-20 08:10:00

EMD: Emyria partners with PAX Centre for MDMA-assisted therapy

EMYRIA LIMITED

2023-03-07 08:15:00

EMD: Emyria secures clinical-grade MDMA supply for Aust patients

EMYRIA LIMITED

2023-02-13 09:33:00

EMD: Emyria expands MDMA programs following landmark TGA decision

EMYRIA LIMITED

2023-02-06 09:25:00

EMD: First dosing commenced for pivotal EMD-RX5 Phase 3 trial

EMYRIA LIMITED

2023-01-30 09:37:00

EMD: Emyria receives $2.1M R&D tax incentive refund

EMYRIA LIMITED

  1. Emyria has received a $2,094,701 R&D Tax Incentive Refund from AusIndustry.
  2. The refund is for the 2018-19 financial year.
  3. The refund will be used to fund the development of Emyria's digital health platform.

2023-01-12 09:41:00